F S&P 500
5,553.50 +7.50 (+0.14%) F Dow Jones
39,512.00 -38.00 (-0.10%) F Nasdaq
20,087.75 +48.25 (+0.24%) E-mini Russell 2000 Index Futur
2,063.60 +3.50 (+0.17%) Petróleo
82.02 +0.28 (+0.34%) Oro
2,331.60 -5.00 (-0.21%)
Zelira Therapeutics Limited (ZLDAF)
Zelira Therapeutics Limited
101 St George's Terrace
Level 3
Perth, WA 6000
Australia
61 8 6558 0886
https://zeliratx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Osagie O. Imasogie Esq. | Founder & Chairman | 95.68k | N/D | 1962 |
| Dr. Oludare Odumosu | MD, Global CEO & Director | 318.11k | N/D | N/D |
| Mr. Greg Blake | Executive Director | 168.28k | N/D | N/D |
| Mr. Timothy Ryan Slate | Company Secretary & Non-Executive Director | 23.92k | N/D | N/D |
| Mr. Rahul Ganesan | Vice President of Finance & Accounting | N/D | N/D | N/D |
| Dr. Patty Washer | Clinical Trial Consultant | N/D | N/D | N/D |
Descripción
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Gestión corporativa
La calificación ISS Governance QuickScore de Zelira Therapeutics Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
